HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN.
Hah JH, et al. Among authors: fooshee dr.
Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20.
Head Neck. 2014.
PMID: 24123531
Free PMC article.